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Background: Data on non-specific effects of BCG vaccination in well described, general population African cohorts
is scanty. We report the effects of BCG vaccination on post-neonatal infant and post-infancy mortality in a cohort of
children in Mbale, Eastern Uganda.
Methods: A community-based prospective cohort study was conducted between January 2006 and February 2014.
A total of 819 eligible pregnant women were followed up for pregnancy outcomes and survival of their children up
to 5 years of age. Data on the children’s BCG vaccination status was collected from child health cards at multiple
visits between 3 weeks and 7 years of age. Data was also collected on mothers’ residence, age, parity, household
income, self-reported HIV status as well as place of birth. Multivariable Cox proportional hazards regression models
taking into account potential confounders were used to estimate the association between BCG vaccination and
child survival.
Results: The neonatal mortality risk was 22 (95% CI: 13, 35), post-neonatal infant mortality 21 (12, 34) per 1,000 live
births and the mortality risk among children between 1 and 5 years of age (post-infancy) was 63 (47, 82) per 1,000
live births. The median age at BCG vaccination was 4 days. Out of 819 children, 647 (79%) had received the BCG
vaccine by 24 weeks of age. In the adjusted analysis, the rate of post-neonatal death among infants vaccinated with
BCG tended to be nearly half of that among those who had not received the vaccine (adjusted HR: 0.47; 95% CI:
0.14, 1.53). BCG vaccination was associated with a lower rate of death among children between 1 and 5 years of
age (adjusted HR: 0.26; 95% CI: 0.14, 0.48).
Conclusion: The risk of early childhood death in Mbale, Uganda is unacceptably high. BCG vaccination was
associated with an increased likelihood of child survival.
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An estimated 145,000 children under five years of age
die each year in Uganda [1] and the country’s under-five
mortality is estimated to be 90 per 1,000 live births [2].
Of these deaths, 63% occur in the first year of life.
Under-five mortality in Uganda has dropped between
1990 and 2012 with an average annual rate of 1.9% [3].
To meet the fourth Millennium Development Goal of
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unless otherwise stated.1990 to 49/1,000 in 2015, an even greater reduction in
the number of child deaths is necessary. Achievement of
this goal depends in part on the identification and im-
plementation of effective child survival interventions [4],
particularly vaccination against common childhood dis-
eases like diphtheria, tetanus, polio, measles, pneumonia
and tuberculosis (TB). In Uganda, children receive the
BCG vaccine at birth or at the first contact with the
health service, primarily to protect them against severe
forms of TB. Studies from Guinea Bissau, Senegal, and
Malawi now indicate that this vaccine may have non-
specific effects on childhood morbidity and mortality that
cannot be solely explained by its protective effect against
tuberculosis [5-9]. It appears that children vaccinated withntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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respiratory tract infections and respiratory syncytial virus
infections [11]. It is posited that the BCG vaccine induces
its non-specific effects via epigenetic reprogramming
of the innate immune cells [12]. A study among human
volunteers showed that with BCG vaccination, the pro-
duction of IFN-γ increased 4–7 times while the release
of cytokines particularly TNF and IL-1β doubled, in
response to non-tuberculous bacterial and fungal path-
ogens [12]. With the incidence of childhood TB declin-
ing in Sub-Saharan Africa, the importance of these
probable non-specific effects is growing.
Yet, the literature supporting these non-specific effects
is scanty and controversial [5]. It has been suggested that
methodological challenges arising from uncontrolled
confounding [13,14] and possibly survival bias in retro-
spective studies [13,15-17] could explain the observed
association between BCG vaccination and child survival.
Routine childhood vaccination, particularly BCG vaccin-
ation is a key child survival intervention. Understanding
this predictor and other local predictors of child survival
is important for child health programmes. But, lack of
vital event registration systems in many low and middle
income countries (LMICs), including Uganda, makes
this difficult [18-20]. The objective of this prospective
community-based cohort study was to estimate the effect
of BCG vaccination on the risk of death among children
under five years of age in Mbale, Eastern Uganda.
Methods
The study was undertaken as part of the cluster-
randomized PROMISE EBF intervention trial, where we
promoted exclusive breastfeeding (EBF) by individual
peer counselling in the intervention areas [21]. Data
collection started in Uganda in January 2006, continued
beyond that of the PROMISE-EBF trial, and ended in
February 2014. We have previously reported on the
perinatal mortality and morbidity during infancy in this
cohort [22].
Study site
The study was conducted in Mbale district, 300 km
North-East of Kampala with an estimated population of
720,000, at the time of study commencement in 2006
[23]. The study area is served by Mbale Regional Referral
Hospital, which double as the district and regional referral
hospital. The HIV prevalence among pregnant women in
antenatal clinics in Mbale was approximately 5% during
the study period. Most of the people living in the area
were subsistence farmers. The study was conducted in the
two biggest of the 7 counties in Mbale district, namely
Bungokho County (rural) and Mbale Municipality (urban).
Twenty four clusters were included in the study, 18 rural
and 6 urban. Six urban clusters in Mbale municipalitywere selected from all its three municipal divisions. Most
of the urban areas were large informal settlements (urban
slums). Eighteen rural clusters in Bungokho County were
chosen from eight out of its eleven sub-counties. Clusters
were included if they neighboured the main road out from
Mbale Municipality or were on the 1st or 2nd branch
off the main road, had a population of at least 1,000 in-
habitants and represented a social and administrative
unit. Children in the study area receive vaccines on the
Ugandan immunization schedule which includes BCG,
DPT-HepB + Hib, polio and measles. BCG vaccine
(BCG-Denmark) is administered intra-dermally, on the
right upper arm at birth or at first contact (dosage
0.05 ml up to 11 months and 0.10mls after the
11 months). DPT-HepB + Hib is administered in three
doses, of 0.5mls each at monthly intervals, starting at
6 weeks (or first contact after that age). Polio is admin-
istered orally, in four doses (2 drops each). The first
dose is given at birth or within the first two weeks and
the subsequent doses are monthly starting at 6 weeks
of age. Measles is given as a single dose at nine months
of age.
Study subjects
Between January 2006 and May 2008, all pregnant
women in the selected clusters were identified by study
recruiters. Recruiters were mostly women representa-
tives on the local village councils in the study area. They
were well respected members of the community, with
good knowledge of the local geography, community
members and social structures. They regularly went door
to door in order to identify new pregnancies. The preg-
nant women were then approached by the study team
and invited to participate in the trial if they resided in
the study area, were seven or more months pregnant,
opted to breastfeed their infants, were not intending to
leave the area during the study period, and consented to
participate in the study. Of the 886 pregnant women
who were identified and approached, 875 (99%) accepted
to participate. Of these, 12 (1.4%) women did not meet
the eligibility criteria and 28 (3.2%) relocated out of the
study area after recruitment, while 16 (1.8%) women expe-
rienced a stillbirth. We analysed data for the remaining
819 women.
Ethics approval was obtained from the Makerere
University Research and Ethics Committee, the Uganda
National Council for Science and Technology, and from
the Regional Committee for Medical and Research
Ethics for Western Norway (REK VEST, approval number
05/8197).
Data collection
At recruitment, trained data collectors fluent in the
local language administered a pre-tested structured
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collected information on the current pregnancy as well
as on socio-demographic characteristics, antenatal care
attendance (ANC) and marital status. After birth, the
mother/child pairs were visited at weeks 3, 6, 12 and
24, between 18–24 months of age, between 3 and
5 years of age and between 5 and 7 years of age. Data
on vaccination, illness and the child’s vital status was
collected at each of the visits. Information on vaccin-
ation status was obtained through maternal interviews
and review of child health cards. To minimize informa-
tion bias, child health card data was prioritized in this
study. A standard World Health Organization (WHO)
verbal autopsy questionnaire that had been validated in
Uganda was used to collect information for a standard
algorithm determining the likely cause of death [24].
The questionnaire had both an open-ended section for
reporting verbatim and a closed-ended section with fil-
ter questions.
Definitions
We categorized marital status into three categories:
‘Married’, ‘Co-habiting’ and ‘Other’. The ‘Other’ category
included women that were divorced, widowed or sepa-
rated. In Uganda, it is now common to find couples
living together without being formally married and we
classified these as ‘Co-habiting’. Place of birth was cate-
gorized into ‘home births’, which were those that took
place at home with or without a traditional birth attend-
ant or those occurring on the way to a health facility.
Health facility births were those that happened at a hos-
pital, clinic or local maternity unit. We defined parity
according to the number of previous live births. Based
on the Ugandan education curriculum in which primary
education is scheduled for seven years, education was
grouped into ‘7 years of school or less’ and ‘more than
7 years of school’. Age was categorized into four categor-
ies (less than 20 years, 20–24, 25–30 and greater than
30 years).
We created a composite index of assets (socio-eco-
nomic status) using multiple correspondence analysis
(MCA). Because the MCA technique allows combination
and ranking of a large number of variables into fewer
variables without prejudgment, it is considered a more
accurate indicator of socioeconomic status (SES) than
single items such as occupation or possession of particu-
lar items [25]. Also, in comparison to principal compo-
nent analysis (PCA), the MCA technique is more
appropriate for discrete variables. This was important in
this study because several relevant variables could only
be categorical. Furthermore, unlike PCA, which clusters
variables together, MCA clusters the categories within
these variables together [25]. We used MCA on posses-
sion of a TV, radio, mobile phone, chair, cupboard,refrigerator, type of toilet, type of house walls as well as
presence of electricity and water in the home. Scores
were obtained and categorized into centiles (the poorest
20%, middle 40% and the richest 40%).
Statistical analysis
Data was analysed with Stata version 9.2 (StataCorp LP,
TX, U.S.). Continuous variables were summarized with
means, standard deviations, medians, ranges and inter-
quartile ranges while percentages were calculated for
categorical variables. The primary outcomes were post-
neonatal infant death and post-infancy death. We calcu-
lated their confidence limits with the exact method. The
neonatal mortality risk was the proportion of deaths
within the first 28 days of life, the infant mortality risk
the proportion of deaths in the first year of life [26], all
per 1,000 live births. Post-neonatal infant mortality risk
was the proportion of deaths between one month and
1 year of age while post-infancy death risk was the pro-
portion of deaths between 1 and 5 years of age. The
main outcome variables were post-neonatal infant death
and post-infancy death. The main exposure variable was
BCG vaccination. Other variables included as potential
confounders included maternal age, parity, mother’s
education, place of birth, antenatal care attendance,
marital status, residence and household wealth index.
In order to take into account variable follow up time,
Cox proportional hazards models were used to estimate
hazard ratios (HR) and 95% confidence intervals. In the
models, BCG vaccinated children contributed person-
time from the date of vaccination with BCG until death,
migration or last follow-up visit while non-vaccinated
children contributed person-time from birth till death,
migration or last follow-up visit. The multivariable re-
gression models included variables which, in a crude
analysis, were associated with deaths yielding a P-value
< 0.25. The final models were also adjusted for the
child’s age in days at the time of vaccination and for the
design effect of the cluster-randomized PROMISE-EBF
trial. We also undertook a so called landmark analysis to
thwart the effects of a possible survival bias induced by
the so-called “immortal person-time” [27].
Results
In this cohort of 819 live born children, 83% were
followed up till death or till five years of age. The mean
age of the mothers was 25 years at inclusion, ranging
from 14 to 44 years with an inter-quartile range (IQR) of
20 to 30 years of age. They had a mean of 7 years of for-
mal education (range 0 to 18 years; IQR 5 to 9 years).
Their mean and median parity was 3 and 2, respectively,
ranging from 0 to 14, with an IQR of 3 to 5. Socio-
demographic factors are presented in the tables. Most of
the households, 667 (81%) were headed by men. Two
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themselves. Among the women who had given birth be-
fore, 201 (25%) had lost at least one live born child.
Fifty-five per cent or 452 of the women reported having
been informed about HIV testing and counselling, 315
(38%) had been counselled and 251 (31%) had been
tested. Out of the 156 that had been tested and knew
their results, 15 (9.6%) reported to be HIV-positive. A
total of 447 women out of 819 women with live births
(55%) delivered at home. There were18 neonatal deaths
constituting 55% of the infant deaths (Figure 1). Neonatal
mortality was 22 (95% CI: 13, 35) per 1,000 live births.
Conditions associated the neonatal deaths and identified
via verbal autopsies were: cord prolapse, obstructed
labour, antepartum haemorrhage, mal-presentations, pre-
term births, malaria and other causes of fever in preg-
nancy, neonatal tetanus and preeclampsia. None of the
neonatal deaths that occurred at home were registered in
the national vital registration system and there was no
death certificate available for any of the deaths, including
those that occurred in the health facilities. The infant
mortality risk was 43 (95% CI: 30, 59) per 1,000 live births
while under-five mortality was 103 (95% CI: 83, 125) per
1,000 live births.
At 6 months of age, 647 children out of a total 819
children had been vaccinated with the BCG vaccine. The835 eligible pregnant
women
819 live births
16 stillbirths
0 <7days
18 deaths
8 <28 days
0 deaths
29days <1year
17deaths
1 <5 years
49 deaths
Figure 1 Child mortality in a cohort of 819 children in Mbale, Easternmedian age at vaccination was 4 days, the IQR included the
day of birth and day 4 after birth, and none of the vacci-
nated children were older than 6 months of age when they
received BCG. Details on vaccination timeliness in this co-
hort have been presented elsewhere [28,29]. Children born
at home and those living in rural areas were less likely to
get vaccinated with BCG in comparison to their counter-
parts born at health facilities or residing in urban areas.
There were no major differences between BCG vaccinated
and unvaccinated children with regards to other back-
ground characteristics recorded in this study (Table 1).
Post-neonatal infant deaths
The 17 post-neonatal infant deaths constituted 49% of
the 33 infant deaths. This translated to a post-neonatal
infant mortality risk of 21 (12, 34) per 1,000 live births
in the cohort of 801 babies. Immediate causes of post-
neonatal infant deaths included malaria, respiratory tract
infections, and diarrhoea. In an analysis in which BCG
vaccinated children contributed time from the registered
date of vaccination, the rate of post-neonatal death
among infants who received the BCG vaccine was half
of that among those who had not been vaccinated (HR:
0.47; 95% CI: 0.14, 1.53). The landmark analysis yielded
a HR of 0.76 (95% CI 0.20, 2.87). Infants whose mothers’
self-reported as HIV positive were 34 times (HR: 34.4;Stillbirth risk:
19(11,31)
per1,000 pregnancies
Perinatal mortality risk
41(27,54)
per1,000 pregnancies
Neonatal mortality risk:
22(13,35)
per1,000 live births
Infant mortality risk:
43(30,59)
per1,000 live births
Under 5mortality risk:
103(83,125)
per1,000 live births
Mortality risks (95%CI)
Uganda.
Table 1 Background characteristics for BCG vaccinated
and BCG unvaccinated children in a cohort of 819
children in Mbale, Eastern Uganda
BCG vaccination status
Variable Unvaccinated N = 172
n (%)
Vaccinated N = 647
n (%)
Maternal age
<20 years 39 (22.7) 142 (22.0)
20-24 51 (29.7) 212 (32.2)
25-29 47 (27.3) 150 (23.2)
≥30 35 (20.6) 143 (22.1)
Parity
0 47 (27.3) 153 (23.7)
1-2 50 (29.1) 198 (30.6)
3-4 38 (22.1) 151 (23.3)
5 or more 37 (21.5) 145 (22.4)
Mother’s education
>7 years 44 (25.6) 196 (30.3)
≤7 years 128 (74.4) 451 (69.7)
Residence
Rural 118 (68.6) 517 (79.9)
Urban 54 (31.4) 130 (20.1)
Marital status
Married 103 (59.9) 402 (62.1)
Co-habiting 47 (27.3) 193 (29.8)
Othera 22 (12.8) 52 (8.04)
Maternal HIV status
Negative 31 (18.0) 110 (17.0)
Positive 5 (2.91) 10 (1.55)
Don’t know 136 (79.1) 527 (81.5)
Household wealth index
Poorest 20% 28 (16.3) 135 (20.9)
Middle 40% 65 (37.8) 261 (40.3)
Richest 40% 79 (45.9) 251 (38.7)
Antenatal care attendance
No 117 (68.0) 473 (73.1)
Yes 55 (32.0) 174 (26.9)
Place of birth
Home/TBA 114 (66.3) 333 (51.5)
Hospital/clinic 58 (33.7) 314 (48.5)
Peer counselling for exclusive breastfeeding
No 88 (51.2) 306 (47.3)
Yes 84 (48.8) 341 (52.7)
aIncludes women that were separated, divorced or widowed.
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period as children whose mothers’ self-reported as HIV
negative (Table 2).Post-infancy deaths
There were 784 children alive at the end of the first year
and 49 of these died between 1 and 5 years of age. The
mortality risk among children in this age group was 63
(95% CI: 47, 82) per 1,000 live births. BCG vaccination
within the first six months was associated with better
survival for this age group in both the unadjusted (HR:
0.38; 95%CI: 0.21, 0.65) and the adjusted (HR: 0.26; 95%
CI: 0.14, 0.48) analysis. The landmark analysis yielded a
HR of 0.33 (95% CI 0.17, 0.64). Women between 25 and
29 years of age were less likely to have a child death in
this age group than women less than 20 years of age in
the adjusted analysis (HR: 0.40; 95% CI: 0.16, 0.99).
There was no association between maternal education
and parity with post-infancy death (Table 3).
Gender and child death
There was no association between the post-neonatal in-
fant’s sex and death (HR for girls versus boys = 1.08; 95%
CI: 0.40, 2.89). Infant gender was not an effect measure
modifier of the relationship between BCG vaccination
and death (p-value for heterogeneity of HRs = 0.876).
Among girls, the HR was 0.52 (95% CI: 0.10, 2.79), while
among boys, the HR was 0.34 (95% CI: 0.05, 2.18). Simi-
larly, there was no association between the 1–4 year old
children’s sex and death (HR: 0.94; 95% CI: 0.53, 1.69),
and gender did not modify the effect of BCG on death
among them (p-value for heterogeneity of HRs = 0.586).
Among girls, the HR for the association between BCG
vaccination and death in this group was 0.34 (95% CI:
0.14, 0.83) while among boys it was 0.22 (95% CI: 0.09,
0.52).
Discussion
This community-based cohort study in Mbale, Eastern
Uganda, presents high risks of child death and reveals
that BCG vaccination in infancy is associated with sur-
vival among children 1–5 years of age. The neonatal
mortality and infant mortality risk estimates of 22 and
43 were compatible with the national Demographic and
Health Survey (DHS) estimates of 27 and 47 per 1,000
live births, respectively [2]. The post-neonatal infant
mortality risk was 23 per 1,000 while the mortality risk
among children between 1 and 5 years of age was 63 per
1,000 children.
The rate of death among 1 to 5 year old children who
had received BCG by six months of age was substantially
lower than among those who had not. BCG vaccine is
routinely administered to children at birth to protect
them against tuberculosis (TB). But several observational
studies now indicate that this vaccine may have non-
specific effects on childhood illness and death that extends
beyond its protective effects against TB [5-9]. A prospect-
ive study of two Senegalese birth cohorts showed that
Table 2 BCG vaccination and post-neonatal infant mortality in a cohort of 801 children in Mbale, Eastern Uganda*a
Variable No. of deaths/total Deaths/1,000 (95% CI) Unadjusted HR (95% CI) Adjusted HR (95% CI)a
BCG vaccination
Yes 12/647 19 (10, 32) 0.57(0.21, 1.52) 0.47 (0.14, 1.53)
No 5/154 32 (11, 74) 1
Maternal age
<20 years 4/178 22 (06, 57) 1
20-24 5/259 19 (06, 44) 0.84 (0.23, 3.12)
25-29 4/192 21 (06, 52) 0.91 (0.23, 3.66)
≥30 4/172 23 (06, 58) 1.31 (0.35, 4.89)
Parity
0 4/195 21 (06, 52) 1
1-2 5/243 21 (07, 47) 1.04 (0.28, 3.86)
3-4 3/185 16 (03, 47) 1.08 (0.27, 4.33)
5 or more 5/178 28 (09, 64) 1.48 (0.40, 5.51)
Mother’s education
>7 years 3/233 13 (03, 37) 1 1
≤7 years 14/568 25 (14, 41) 2.05 (0.59, 7.08) 1.62 (0.36, 7.40)
Residence
Rural 15/624 24 (14, 39) 1 1
Urban 2/177 11 (01, 40) 0.41 (0.09, 1.77) 1.26 (0.20, 7.98)
Marital status
Married 11/494 22 (11, 39) 1
Co-habiting 3/234 13 (03, 37) 0.52 (0.15, 1.84)
Otherb 3/73 41 (09, 115) 1.58 (0.45, 5.59)
Maternal HIV status
Negative 1/140 07 (00, 39) 1 1
Positive 2/14 143 (18, 428) 24.33 (2.12, 268.33) 34.44 (2.91, 407.06)
Don’t know 14/647 22 (12,36) 3.15 (0.42, 23.81) 2.07 (0.26, 16.78)
Household wealth index
Poorest 20% 6/157 38 (14, 81) 1 1
Middle 40% 8/321 25 (11, 49) 0.76 (0.27, 2.14) 0.60 (0.20, 1.84)
Richest 40% 3/323 09 (02, 27) 0.25 (0.06, 1.01) 0.16 (0.03, 0.88)
Antenatal care attendance
No 8/223 36 (16, 69) 2.00 (0.79, 5.07) 1.84 (0.63, 5.35)
Yes 9/578 16 (07, 29) 1 1
Place of birth
Home/TBA 11/430 26 (13, 45) 1.62 (0.61, 4.32)
Hospital/clinic 6/371 16 (06, 35) 1
Peer counselling for exclusive breastfeeding
No 9/387 23 (11, 44) 1.04 (0.41, 2.62)
Yes 9/414 19 (08, 38) 1
*CI indicates confidence interval and HR indicates hazards ratio(s) obtained from Cox proportional hazards models.
aThe HRs are adjusted for the variables for which a HR is given as well as for age of the child in days at the time of receiving the BCG vaccine. Clustering by the
randomization units in the PROMISE-EBF trial was also taken into account.
bIncludes women that were separated, divorced or widowed.
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Table 3 BCG vaccination and death in a cohort of 784 children between 1 and 5 years age in Mbale, Eastern Uganda*
Variable No. of deaths/total Deaths/1,000 (95% CI) Unadjusted HR (95% CI) Adjusted HR (95% CI)a
BCG vaccination
Yes 29/635 46 (31, 65) 0.38(0.21, 0.65) 0.26 (0.14, 0.48)
No 20/149 134 (84, 200) 1
Maternal age
<20 years 16/174 92 (53, 145) 1 1
20-24 15/254 59 (33, 96) 0.65 (0.33, 1.31) 0.70 (0.33, 1.47)
25-29 7/188 37 (15, 75) 0.40 (0.16, 0.96) 0.40 (0.16, 0.99)
≥30 11/168 65 (33, 114) 0.73 (0.34, 1.57) 0.69 (0.31, 1.56)
Parity
0 11/191 58 (29, 101) 1
1-2 17/238 71 (42, 112) 1.13 (0.54, 2.36)
3-4 9/182 49 (23, 92) 0.78 (0.33, 1.86)
5 or more 12/173 69 (36, 118) 1.16 (0.52, 2.59)
Mother’s education
>7 years 15/230 65 (37, 105) 1
≤7 years 34/554 61 (43, 85) 0.97 (0.53, 1.77)
Residence
Rural 44/609 72 (53, 96) 1 1
Urban 5/175 29 (09, 65) 0.45 (0.19, 1.10) 0.51 (0.16, 1.59)
Marital status
Married 34/483 70 (49, 97) 1 1
Co-habiting 14/231 61 (34, 100) 0.82 (0.44, 1.53) 0.93 (0.48, 1.79)
Otherb 1/70 14 (00, 77) 0.18 (0.02, 1.32) 0.15 (0.02, 1.10)
Maternal HIV status
Negative 8/139 58 (25,110) 1 1
Positive 2/12 167 (21, 484) 3.09 (0.66, 14.58) 1.82 (0.22, 15.14)
Don’t know 39/633 62 (44,83) 1.07 (0.50, 2.28) 1.11 (0.49, 2.51)
Household wealth index
Poorest 20% 9/151 60 (28, 110) 1
Middle 40% 23/313 73 (47, 108) 1.23 (0.58, 2.73)
Richest 40% 17/320 53 (31, 84) 0.97 (0.44, 2.16)
Antenatal care attendance
No 16/215 74 (43, 118) 1.20 (0.66, 2.18)
Yes 33/569 58 (40, 80) 1
Place of birth
Home/TBA 30/419 72 (49, 101) 1.33 (0.75, 2.36)
Hospital/clinic 19/365 52 (32, 80) 1
Peer counselling for exclusive breastfeeding
No 18/378 48 (28, 74) 0.64 (0.36,1.13)
Yes 31/406 76 (52, 107) 1
*CI indicates confidence interval and HR indicates hazards ratio(s) obtained from Cox proportional hazards models.
aModel adjusted for age of the child in days and clustering to take into account the design of the PROMISE-EBF trial.
bincludes women that were separated, divorced or widowed.
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had a lower mortality compared to those that had not
[17]. Other observational studies have linked BCG vaccin-
ation and/or presence of the BCG scar with reduced inci-
dence of acute lower respiratory tract infections [11] and
septicaemia among [10] infants. These potential non-
specific effects of BCG and other childhood vaccines are
growing in importance especially as the incidence of TB
and of other target diseases among children decrease.
Unsurprisingly, none of the deaths that occurred at
home were recorded in any formal system or had a
death certificate. Many of these deaths would therefore
have been missed by facility-based studies and the early
neonatal deaths of mothers dying during or shortly after
birth could also have been missed by retrospective sur-
veys which are the principle sources of data on mortality
in low and middle income countries. This prospective
study was able to capture these deaths that would have
otherwise not been counted in other designs. The ab-
sence of a functioning vital event registration system
highlights the need to establish a pregnancy or repro-
ductive health registry if one is to adequately describe
trends as well as predictors’ child health and survival in
populations such as this one.
This was a prospective study with good ascertainment
of deaths. However, there could have been an underesti-
mation of neonatal deaths because the distinction be-
tween early neonatal deaths and stillbirths is difficult,
particularly in home births where there are no skilled
health workers who can identify faint signs of life
[30-32]. Additionally, some stillbirths could have been
misclassified as first hour deaths [31]. But, the propor-
tion of stillbirths and early neonatal deaths in our cohort
is in line with WHO estimates for East Africa [33]. Ver-
bal autopsies were used in this study to ascertain likely
causes of neonatal deaths. Though verbal autopsies are
generally accepted in many countries without vital regis-
tration, their validity and sensitivity varies widely be-
tween locations [34]. In this study, we used a standard
WHO verbal autopsy tool that has been validated in
Uganda [24]. Because neonatal and infant deaths were
few, some of our estimates are imprecise. Several relevant
variables were considered and were found not to positively
confound the association between BCG vaccination
and child survival. In fact, adjustment for confounders
strengthened rather than weakened the association be-
tween BCG vaccination and child survival. Still it is pos-
sible, that some of the association could be ascribed to
confounding if children with a lower mortality were more
likely to be vaccinated compared to those with a higher
mortality. It was not possible to adequately adjust for the
potential confounding effect of the child’s HIV status as
HIV testing was not done for the children and only a
quarter of the mothers were aware of their HIV status.Vaccination data in this study was collected prospect-
ively and validated with vaccination cards before almost
all the deaths happened. Our finding is therefore un-
likely to be explained by survival bias that has been
reported in some retrospective studies in Africa in which
child deaths were associated with missing vaccination
cards that were destroyed or in other ways lost soon
after the deaths [13,14,27]. Still, we undertook a land-
mark analysis which intends to circumvent a survival
bias that artificially inflates the association between vac-
cination and survival [27]. The association between
infant BCG vaccination and survival among 1 to 5 year
old children only slightly weakened, a change that may
just as well be ascribed to the non-differential misclassi-
fication inherent in this type of analysis [27]. Our ana-
lysis among the post-neonatal infants may have slightly
over-estimated the death rate in the children who had
not received BCG because in those that had, person-
time accrual did not start at birth but when they were
vaccinated. However, this possible overestimation is
likely to be small as only 12% of the vaccinated children
had not received BCG by the time they were 4 weeks of
age and the HR was adjusted for age. Any such overesti-
mation would not be operational in the analysis of the
association between BCG vaccination and death rate
among children aged 1 to 5 years because all children in
the BCG vaccinated group had been vaccinated by six
months of age.
This was a secondary analysis of a data from random-
ized trial. As such, we did not have data on all the rele-
vant risk factors for child survival or all potential
confounding factors for the association between BCG
and child survival in Mbale. Importantly, nearly 50% of
the children were born at home and were not weighed
at birth. This limited our ability to study birth weight as
a predictor of death in this cohort, or to examine its
effect on the association between BCG vaccination and
child survival. Only 17% of the 819 live born children
migrated out of the study area and were lost to follow
up before five years of age. There were no major differ-
ences in background characteristics between children
lost to follow-up and those who remained in the study.
Conclusion
The risk of childhood death remains unacceptably high
and is an important public health problem in Mbale,
Uganda. BCG vaccination within the first six months of
life was associated with a lower incidence of death
among children between 1 and 5 years of age.
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